THE HEALTH CARE COSTS OF LONG-ACTING INSULIN ANALOGS COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES USING A BASAL REGIMEN: A DANISH PERSPECTIVE

被引：0
|
作者：
Gundgaard, J. [1 ]
Christensen, T. [2 ]
Thomsen, T. L. [2 ]
机构：
[1] COWI, Kongens Lyngby, Denmark
[2] Novo Nordisk AS, Virum, Denmark
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72264-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A57 / A57
页数：1
相关论文
共 50 条
  • [31] The utilisation of long-acting insulin analogues and intermediate-acting insulin in patients with type 2 diabetes in the United Kingdom
    Brunetti, V. C.
    Yu, O. H. Y.
    Platt, R. W.
    Filion, K. B.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S146 - S146
  • [32] Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes
    C. Schmid
    P. Krayenbühl
    P. Wiesli
    Diabetologia, 2009, 52 : 2668 - 2669
  • [33] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    DIABETES OBESITY & METABOLISM, 2014, 16 (04): : 366 - 375
  • [34] Insulin therapy in type 2 diabetes:: role of the long-acting insulin glargine analogue
    Yki-Järvinen, H
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) : 410 - 416
  • [35] Pharmacoeconomic analysis of insulin glargine compared with NPH insulin in patients with type 2 diabetes in Spain
    Terres, CR
    Rodríguez, J
    Bolinder, B
    De Pablos, P
    DIABETES, 2004, 53 : A291 - A291
  • [36] Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Patients With Type 1 Diabetes
    Rosenstock, Julio
    Bergenstal, Richard M.
    Blevins, Thomas
    Morrow, Linda A.
    Prince, Melvin J.
    Qu, Yongming
    Sinha, Vikram P.
    Howey, D. C.
    Jacober, Scott J.
    DIABETES, 2012, 61 : A263 - A263
  • [37] Restoration of Postprandial Insulin Secretion with Long-Acting Basal Insulin. Replacement in Korean Type 2 Diabetes Patients on Sulfonylurea Based Treatment
    Cho, Jae Hyoung
    Shin, Jeong Ah
    Kim, Min Hee
    Kim, Ji Won
    Ham, Dong Sik
    Sun, Cheng Lin
    Park, Shin Ae
    Lee, Seung Hwan
    Kwon, Hyuk Sang
    Ahn, Yu Bae
    Yoon, Kun Ho
    DIABETES, 2009, 58 : A535 - A535
  • [38] Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis
    Monami, M.
    Marchionni, N.
    Mannucci, E.
    DIABETES OBESITY & METABOLISM, 2009, 11 (04): : 372 - 378
  • [39] Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes: results of a cross-sectional cost evaluation study of long-acting Insulin glargine compared with NPH insulin in Germany (LIVE-DE)
    Hauner, H.
    Kohlmann, T.
    Landgraf, W.
    Holle, R.
    Pirk, O.
    Scholten, T.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2009, 134 (23) : 1207 - 1213
  • [40] Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes
    Edith M. Heintjes
    Trine L. Thomsen
    Fernie J. A. Penning-van Beest
    Torsten E. Christensen
    Ron M. C. Herings
    Advances in Therapy, 2010, 27 : 211 - 222
12345